Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


Revenue 2017


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. MabThera/Rituxan was produced by Roche.

Deal Watch October 2016

Deal Watch October 2016 Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development.

Roche in "unprecedented" launch period for new medicines

Roche in Two of Roche's other big sellers - MabThera/Rituxan (rituximab) and Avastin (bevacizumab) - managed to grow slightly despite competition and pricing pressure. ... Avastin is already facing biosimilar competition in some emerging markets and MabThera

AbbVie and Roche's leukaemia drug venetoclax nears EU market

AbbVie and Roche's leukaemia drug venetoclax nears EU market It is also being tested in combination with Roche's $7bn brand MabThera/Rituxan (rituximab), which is widely-used for CLL, as well as Imbruvica which also cleared $1.2bn in

AbbVie's venetoclax set for early access in UK

AbbVie's venetoclax set for early access in UK up indications such as first-line CLL, combination CLL therapy with Roche's MabThera/Rituxan (rituximab), non-Hodgkin's lymphoma (NHL), acute myeloid leukaemia (AML) and multiple myeloma.

Roche says Tecentriq "off to a good start"

Roche says Tecentriq Roche's top-selling drug MabThera/Rituxan (rituximab) - approved for several indications including non-Hodgkin's lymphoma and CLL - also managed a 4% increase to 3.7bn francs. .

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts


Add my company

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...